Teva Pharmaceutical Industries (TEVA) Competitors

→ only trade options on these 5-7 stocks (From Prosper Trading Academy) (Ad)

$17.16

0.00 (0.00%)

(As of 03:27 PM ET)

TEVA vs. TAK, ALNY, GMAB, RPRX, BMRN, BGNE, VTRS, UTHR, RDY, and SRPT

Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.

Teva Pharmaceutical Industries vs.

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.

: Takeda Pharmaceutical currently has a consensus price target of $14.00, indicating a potential upside of 7.03%. Teva Pharmaceutical Industries has a consensus price target of $15.88, indicating a potential downside of 7.76%. Given Teva Pharmaceutical Industries' higher possible upside, equities analysts clearly believe Takeda Pharmaceutical is more favorable than Teva Pharmaceutical Industries.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Teva Pharmaceutical Industries
0 Sell rating(s)

2 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.75
: Takeda Pharmaceutical has a net margin of 6.18% compared to Takeda Pharmaceutical's net margin of -2.88%. Takeda Pharmaceutical's return on equity of 37.33% beat Teva Pharmaceutical Industries' return on equity.
Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical 6.18% 9.92% 4.71%
Teva Pharmaceutical Industries -2.88% 37.33% 6.73%
: In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Teva Pharmaceutical Industries and 5 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 0.57 beat Takeda Pharmaceutical's score of 0.51 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
: Teva Pharmaceutical Industries received 1214 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.63% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Company Underperform Outperform
Takeda Pharmaceutical Outperform Votes
100
56.82%
Underperform Votes
76
43.18%
Teva Pharmaceutical Industries Outperform Votes
1314
67.63%
Underperform Votes
629
32.37%
: 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Takeda Pharmaceutical $28.20B 1.48 $994.06M $0.55 23.95
Teva Pharmaceutical Industries $15.85B 1.22 -$559M -$0.41 -41.66
: Takeda Pharmaceutical has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Teva Pharmaceutical Industries	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	6.18%	9.92%	4.71%
Teva Pharmaceutical Industries	-2.88%	37.33%	6.73%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Teva Pharmaceutical Industries	Outperform Votes 1314 67.63%	Underperform Votes 629 32.37%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.20B	1.48	$994.06M	$0.55	23.95
Teva Pharmaceutical Industries	$15.85B	1.22	-$559M	-$0.41	-41.66

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

Ad Prosper Trading Academy

only trade options on these 5-7 stocks

I'm going to reveal the only 5-7 stocks you should be trading. But here's the secret - there's nothing special about these stocks. What matters is the repeatable options trading system I use to trade them.

Click here to download my options trading cheat sheet (5-7 stocks inside here)

Get Teva Pharmaceutical Industries News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TEVA vs. The Competition

Export to Excel

Metric	Teva Pharmaceutical Industries	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$19.35B	$6.80B	$4.92B	$17.43B
Dividend Yield	N/A	2.75%	5.25%	3.62%
P/E Ratio	-41.66	8.78	106.95	20.33
Price / Sales	1.22	256.98	2,261.84	14.15
Price / Cash	4.88	19.72	30.37	15.53
Price / Book	2.36	5.82	4.87	4.62
Net Income	-$559M	$143.28M	$105.36M	$972.13M
7 Day Performance	1.40%	6.96%	117.27%	3.62%
1 Month Performance	4.88%	4.46%	117.57%	-2.42%
1 Year Performance	126.53%	-6.02%	125.28%	8.72%

Teva Pharmaceutical Industries Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	0.4855 of 5 stars	$13.34 -1.3%	$14.00 +4.9%	-18.6%	$42.76B	$28.20B	24.25	49,095
ALNY Alnylam Pharmaceuticals	4.6651 of 5 stars	$156.43 +1.9%	$216.19 +38.2%	-20.4%	$19.41B	$1.83B	-58.37	2,100	Options Volume Positive News
GMAB Genmab A/S	3.2534 of 5 stars	$27.32 -2.1%	$49.25 +80.3%	-32.4%	$18.46B	$2.39B	22.77	2,204	Positive News
RPRX Royalty Pharma	4.8868 of 5 stars	$27.42 +0.1%	$43.00 +56.8%	-15.6%	$16.36B	$2.36B	20.46	51	Positive News
BMRN BioMarin Pharmaceutical	4.8715 of 5 stars	$83.87 +1.1%	$106.11 +26.5%	-13.3%	$15.75B	$2.42B	78.38	3,401	Short Interest ↓ Positive News
BGNE BeiGene	2.4308 of 5 stars	$158.59 +1.6%	$251.93 +58.9%	-18.8%	$14.94B	$2.46B	-20.95	10,600	Short Interest ↓ Positive News
VTRS Viatris	0.6204 of 5 stars	$10.64 +1.2%	$11.00 +3.4%	-1.2%	$12.51B	$15.43B	-177.33	38,000
UTHR United Therapeutics	3.9888 of 5 stars	$275.76 +0.2%	$309.44 +12.2%	+25.1%	$12.21B	$2.33B	13.04	1,168	Insider Selling
RDY Dr. Reddy's Laboratories	0.8732 of 5 stars	$72.02 -0.8%	$81.00 +12.5%	+19.2%	$12.11B	$3.35B	17.87	25,863	Short Interest ↑
SRPT Sarepta Therapeutics	4.7619 of 5 stars	$121.38 -1.0%	$164.00 +35.1%	-5.8%	$11.59B	$1.24B	1,103.45	1,314	Analyst Forecast Positive News